AbbVie Continues Deal-Making Spree With $200M Nimble Buy
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of emraclidine in schizophrenia and in anticipation of market erosion for Skyrizi and Rinvoq,
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...
AbbVie has announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, ...
AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s ...
With thousands of press releases published each week, it can be difficult to keep up with everything on . To help healthcare ...
today announced that AbbVie has closed its $1.4 billion acquisition of RA Capital's portfolio company Aliada Therapeutics. Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate ...
AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a ...
The transaction comes less than two months after AbbVie agreed to pay $1.4 billion in cash to acquire Aliada Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback